ELECSYS TOTAL PSA IMMUNOASSAY AND TOTAL PSA CALSET

Total, Prostate Specific Antigen (noncomplexed & Complexed) For Detection Of Prostate Cancer

FDA Premarket Approval P990056

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

Approval for the elecsys(r) total psa immunoassay and elecsys(r) total psa calset. The device, a quantitative in vitro diagnostic test for total prostate-specific antigen (tpsa) in human serum and plasma is indicated for the measurement of total psa in conjunction with dogota; rectal exam (dre) as an aid in the detection of prostate cancer in men aged 50 years or older. Prostate biopsy is required for the diagnosis of prostate cancer. The test id further indicated for serial measurement of tpsa to aid in the management of prostate cancer patients. The electochemiluminescence immunoassay "eclia" is intended for use on the roche elecsys(r) 1010 and 2010 immunoassay analyzers.

DeviceELECSYS TOTAL PSA IMMUNOASSAY AND TOTAL PSA CALSET
Classification NameTotal, Prostate Specific Antigen (noncomplexed & Complexed) For Detection Of Prostate Cancer
Generic NameTotal, Prostate Specific Antigen (noncomplexed & Complexed) For Detection Of Prostate Cancer
ApplicantROCHE DIAGNOSTICS CORP.
Date Received1999-10-04
Decision Date2000-11-22
Notice Date2000-12-12
PMAP990056
SupplementS
Product CodeMTF
Docket Number00M-1660
Advisory CommitteeImmunology
Expedited ReviewNo
Combination Product No
Applicant Address ROCHE DIAGNOSTICS CORP. 9115 Hague Rd. indianapolis, IN 46250
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P990056Original Filing
S038 2021-10-18 30-day Notice
S037 2019-11-14 Normal 180 Day Track
S036 2019-01-29 Real-time Process
S035 2018-10-26 Normal 180 Day Track No User Fee
S034 2018-10-01 30-day Notice
S033 2018-04-17 Real-time Process
S032 2018-04-03 30-day Notice
S031 2018-03-01 Real-time Process
S030
S029 2017-10-11 Real-time Process
S028 2017-07-31 Normal 180 Day Track
S027 2017-08-03 30-day Notice
S026 2017-05-24 30-day Notice
S025 2016-10-26 30-day Notice
S024 2016-09-07 Normal 180 Day Track No User Fee
S023 2016-02-18 30-day Notice
S022 2015-10-07 30-day Notice
S021 2014-04-04 Real-time Process
S020 2013-04-09 Real-time Process
S019 2012-11-30 30-day Notice
S018
S017 2012-02-29 30-day Notice
S016 2012-01-31 135 Review Track For 30-day Notice
S015 2011-11-22 30-day Notice
S014 2011-08-01 Normal 180 Day Track
S013 2011-05-03 Normal 180 Day Track No User Fee
S012 2011-04-25 30-day Notice
S011 2011-04-11 135 Review Track For 30-day Notice
S010 2009-10-07 135 Review Track For 30-day Notice
S009 2008-09-02 30-day Notice
S008 2008-03-28 Normal 180 Day Track
S007 2007-08-22 Normal 180 Day Track
S006 2006-12-28 30-day Notice
S005
S004 2006-10-05 Real-time Process
S003 2006-02-13 Normal 180 Day Track
S002 2006-01-23 Special (immediate Track)
S001 2001-10-09 Normal 180 Day Track

NIH GUDID Devices

Device IDPMASupp
04015630921515 P990056 000
04015630920754 P990056 000
04015630920877 P990056 001
07613336154380 P990056 024
04015630920877 P990056 024
04015630921515 P990056 024
04015630939824 P990056 028
07613336166000 P990056 037
07613336165997 P990056 037
07613336165980 P990056 037
07613336167496 P990056 037

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.